Does Blue Cross Blue Shield of Arizona Cover Dupixent?

How BCBSAZ Classifies Dupixent on Its Formulary

Blue Cross Blue Shield of Arizona places Dupixent on its specialty pharmacy tier across most commercial, individual marketplace (ACA), and Medicare Advantage plans. Specialty-tier placement means the drug is dispensed through a designated specialty pharmacy rather than a retail location, and copay or coinsurance rates are higher than those for preferred brands.

BCBSAZ formularies distinguish between "preferred specialty" and "non-preferred specialty" tiers. Dupixent typically sits on the preferred specialty tier for atopic dermatitis and asthma indications, reflecting its status as the first FDA-approved biologic targeting interleukin-4 receptor alpha (IL-4Rα) [1]. For newer indications like eosinophilic esophagitis (EoE), tier placement can differ between plan years. Checking your specific Summary of Benefits and Coverage (SBC) document is the most reliable way to confirm which tier applies to your plan. BCBSAZ members can verify tier status through the online formulary lookup tool or by calling the member services number on the back of their insurance card.

The distinction matters financially. On a preferred specialty tier, members might pay 20-30% coinsurance after deductible. Non-preferred specialty coinsurance can climb to 40-50%. Annual out-of-pocket maximums, which the ACA caps at $9,200 for individual plans in 2025, still apply and will eventually limit total spending regardless of tier.

Prior Authorization Requirements

Every BCBSAZ plan requires prior authorization (PA) before a pharmacy can dispense Dupixent. The prescribing physician's office must submit clinical documentation proving the patient meets specific medical criteria.

For moderate-to-severe atopic dermatitis, BCBSAZ's medical policy generally requires documentation of diagnosis confirmed by a dermatologist, evidence that the condition affects a significant percentage of body surface area (typically 10% or more in adults), and failure or intolerance of at least one topical corticosteroid and one topical calcineurin inhibitor such as tacrolimus or pimecrolimus [2]. For patients aged 6 months to 17 years, the same documentation standards apply, though body surface area thresholds may be adjusted.

Asthma-related PA criteria are more specific. The prescriber must demonstrate that the patient has moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma, along with blood eosinophil counts of 150 cells/μL or higher, or a fractional exhaled nitric oxide (FeNO) level of 25 ppb or above [3]. A history of two or more exacerbations in the prior 12 months despite adherence to medium- or high-dose inhaled corticosteroids plus a second controller is standard.

PA decisions typically arrive within 5 to 15 business days for standard requests. Urgent (expedited) reviews can be completed in 24 to 72 hours when the prescriber documents that a delay would seriously jeopardize the patient's health.

Step Therapy: What You Must Try First

Step therapy protocols require patients to try and fail less expensive treatments before the insurer authorizes a costlier drug. BCBSAZ applies step therapy to Dupixent for most indications.

For atopic dermatitis, the typical step therapy sequence begins with high-potency topical corticosteroids (such as clobetasol 0.05%) used for an adequate trial period of at least 4 to 8 weeks. The second step involves topical calcineurin inhibitors or, in some plan designs, systemic immunosuppressants like methotrexate, cyclosporine, or mycophenolate mofetil [4]. Dupixent becomes available at step three after documented failure, contraindication, or intolerance of the preceding agents.

For asthma, step therapy follows Global Initiative for Asthma (GINA) guidelines: patients must have been on medium- or high-dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combinations for a minimum of 3 months [5]. Some plans also require a trial of a leukotriene receptor antagonist like montelukast. The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated that dupilumab reduced severe asthma exacerbations by 47.7% in patients with baseline eosinophils of 300 cells/μL or higher, providing the clinical rationale insurers use to justify eventual approval after step therapy completion [6].

Not all step therapy requirements are identical across BCBSAZ products. Self-funded employer plans that use BCBSAZ as a third-party administrator may have more or fewer required steps, depending on the employer's benefit design. Ask your HR department or benefits coordinator if your plan is self-funded.

Estimated Out-of-Pocket Costs for BCBSAZ Members

The wholesale acquisition cost of Dupixent is approximately $3,900 per 300 mg prefilled syringe, translating to roughly $46,800 annually for patients on the every-two-week maintenance dosing schedule [7]. What a BCBSAZ member actually pays depends on plan design, deductible status, and whether they qualify for financial assistance.

A BCBSAZ commercial PPO member with a $2,000 deductible and 30% specialty-tier coinsurance would face the full price per syringe until meeting the deductible, then pay roughly $1,170 per fill (30% of $3,900) until reaching the plan's out-of-pocket maximum. For a member whose out-of-pocket max is $8,550, total annual spending on Dupixent alone could reach that ceiling within the first few months of therapy.

Medicare Advantage members face different cost-sharing. Under Part D specialty-tier rules, coinsurance typically runs 25-33% after the deductible phase, but catastrophic coverage kicks in after $8 to 000 in true out-of-pocket spending (2025 threshold per the Inflation Reduction Act provisions), capping monthly costs for the remainder of the year.

Regeneron's MyWay copay assistance program covers up to $13,000 per year in out-of-pocket costs for commercially insured patients, potentially reducing the copay to $0 [8]. This program does not apply to government-funded insurance (Medicare, Medicaid, Tricare). For those patients, Regeneron offers a separate Patient Assistance Program that provides Dupixent at no cost to qualifying individuals whose household income falls below 400% of the federal poverty level.

Which Conditions Does BCBSAZ Cover Dupixent For?

The FDA has approved dupilumab for six distinct indications as of 2025, and BCBSAZ coverage tracks these approvals, though with varying enthusiasm across plan types.

Atopic dermatitis remains the most straightforward approval pathway. Dupixent was the first biologic approved for moderate-to-severe atopic dermatitis in adults (2017) and later in adolescents (2019) and children as young as 6 months (2022) [1]. The LIBERTY AD SOLO 1 trial (N=671) showed that 38% of dupilumab-treated adults achieved clear or almost-clear skin (IGA 0/1) at 16 weeks, compared with 10% on placebo [9]. BCBSAZ consistently covers this indication after step therapy.

Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependence is the second most common approval. Coverage requires baseline eosinophil documentation.

Chronic rhinosinusitis with nasal polyps (CRSwNP) gained FDA approval in 2019. The SINUS-52 trial (N=448) demonstrated significant improvements in nasal polyp score and nasal congestion severity, with a mean polyp score reduction of 1.71 points versus placebo at 24 weeks [10]. BCBSAZ generally covers this indication but may require documentation of prior endoscopic sinus surgery or failure of intranasal corticosteroids for at least 8 weeks.

Eosinophilic esophagitis (EoE) approval came in 2022, making Dupixent the first and, for some time, only FDA-approved therapy for EoE in patients aged 1 year and older weighing at least 15 kg [11]. Coverage for EoE can be more restrictive. Some BCBSAZ plans require endoscopic confirmation of active eosinophilic inflammation (peak eosinophil count of 15 or more per high-power field on esophageal biopsy) and failure of proton pump inhibitor therapy for at least 8 weeks.

Prurigo nodularis and COPD with type 2 inflammation are the newest approved indications. Coverage policies for these may still be evolving. The LIBERTY-PN PRIME trial (N=151) showed a 60% reduction in itch (as measured by the Worst Itch Numerical Rating Scale) at 24 weeks with dupilumab versus 37% with placebo [12]. For COPD, the BOREAS trial (N=939) demonstrated a 30% reduction in moderate-to-severe exacerbations in patients with blood eosinophils of 300 cells/μL or more [13].

How to Submit a Prior Authorization Request

The PA process begins with your prescribing physician. Here is the typical workflow for BCBSAZ.

Your doctor's office completes a PA request form, which can be submitted electronically through the BCBSAZ provider portal, by fax, or by phone. Electronic submission is fastest. The form requires the patient's member ID, diagnosis code (ICD-10), prescribed dose and frequency, clinical documentation of disease severity, and records of previous treatments attempted and their outcomes.

Supporting documentation should include recent lab results (eosinophil counts for asthma, IgE levels if available), photographs of skin involvement for atopic dermatitis, pulmonary function test results for asthma, or endoscopy reports for EoE and CRSwNP. The more complete the initial submission, the lower the chance of a request for additional information that delays the decision.

BCBSAZ contracts with pharmacy benefit managers (PBMs) that handle specialty drug PA review. The reviewer, typically a clinical pharmacist, evaluates the submission against the plan's medical policy criteria. If approved, the authorization is usually valid for 12 months, after which a renewal (re-authorization) with updated clinical documentation is required. Dr. Jonathan Silverberg, a dermatologist at George Washington University, has noted: "Insurance authorization for biologics like dupilumab often depends more on the quality of documentation than on the severity of disease. Clinicians who submit thorough records see fewer denials" [14].

What to Do If BCBSAZ Denies Your Dupixent Claim

Denials happen. A 2023 IQVIA analysis estimated that approximately 25-30% of initial specialty biologic PA requests are denied across commercial payers nationally [15]. The good news: a significant proportion of these denials are overturned on appeal.

The denial letter from BCBSAZ will specify the reason. Common reasons include incomplete documentation, failure to complete step therapy, off-label use, or the reviewer's determination that medical necessity criteria were not met. Read the denial letter carefully. It is a roadmap showing exactly what the insurer wants to see.

Level 1 (Internal Appeal): Your physician submits a written appeal with additional clinical documentation addressing the specific denial reason. Include peer-reviewed literature supporting Dupixent use for your condition, updated labs, clinical photographs, and a letter of medical necessity from your specialist. BCBSAZ must complete internal appeal review within 30 days for standard requests or 72 hours for urgent/expedited appeals under ACA regulations.

Level 2 (External Review): If the internal appeal is denied, Arizona law and federal ACA rules give you the right to an independent external review. An external review organization (ERO) not affiliated with BCBSAZ reviews the case. The ERO's decision is binding on the insurer. The Arizona Department of Insurance and Financial Institutions oversees this process.

Peer-to-Peer Review: Before or during the appeal, your prescribing physician can request a peer-to-peer phone consultation with the BCBSAZ medical director. These conversations allow your doctor to present the clinical case directly, and they often resolve denials faster than written appeals alone. According to a 2022 survey published in the Journal of Managed Care & Specialty Pharmacy, peer-to-peer reviews reversed initial denials in approximately 42% of specialty drug cases [16].

Dupixent Coverage for Children on BCBSAZ Plans

Pediatric coverage follows the same PA and step therapy framework as adult coverage, with age-appropriate modifications. Dupixent is FDA-approved for atopic dermatitis in children as young as 6 months and for asthma in children aged 6 and older [1].

For children with atopic dermatitis, BCBSAZ requires documentation that the condition is moderate-to-severe (typically using the Eczema Area and Severity Index, EASI, or the Scoring Atopic Dermatitis, SCORAD, tool) and that topical therapies were inadequate. The LIBERTY AD PEDS trial (N=367) in children aged 6 months to 5 years showed that 28% of dupilumab-treated patients achieved IGA 0/1 at 16 weeks versus 4% on placebo [17].

Weight-based dosing applies to pediatric patients. Children weighing 5 kg to <15 kg receive 200 mg every 4 weeks, those 15 kg to <30 kg receive 300 mg every 4 weeks, and those 30 kg to <60 kg receive 200 mg every 2 weeks [1]. These dosing differences do not affect coverage eligibility but are verified during the PA process to confirm appropriate prescribing.

Arizona's Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit under Medicaid requires coverage of FDA-approved drugs for children under 21 when medically necessary, which can sometimes provide broader access than commercial BCBSAZ plans for Medicaid-eligible children.

Specialty Pharmacy and Delivery Logistics in Arizona

BCBSAZ requires Dupixent to be dispensed through an in-network specialty pharmacy. The plan's preferred specialty pharmacy partners handle order processing, cold-chain shipping (Dupixent requires refrigeration at 2-8°C), and patient education on self-injection technique.

Initial orders typically include a starter kit with the loading dose syringes and educational materials. Refills are coordinated on a recurring schedule, and the specialty pharmacy usually contacts patients 5 to 7 days before each shipment to confirm delivery details and assess for adverse effects.

Patients in rural Arizona areas receive the same home-delivery service as those in Phoenix or Tucson metro areas. Shipping is temperature-controlled with insulated packaging and cold packs. If a shipment arrives with a compromised cold chain (e.g., warm to touch, ice packs fully melted), patients should contact the specialty pharmacy immediately for a replacement rather than using the medication.

BCBSAZ members should confirm their plan's designated specialty pharmacy before the prescriber sends the prescription. Using an out-of-network specialty pharmacy can result in claim denial or significantly higher cost-sharing. The BCBSAZ member portal lists in-network specialty pharmacy options, and the MyWay program can also help coordinate pharmacy selection.

How Dupixent Coverage Compares to Other Biologics on BCBSAZ

BCBSAZ covers several biologics that overlap with Dupixent's indications. Understanding how the plan positions these alternatives helps contextualize the PA and step therapy requirements.

For atopic dermatitis, JAK inhibitors like abrocitinib (Cibinqo) and upadacitinib (Rinvoq) are oral alternatives that BCBSAZ also covers with PA. These agents carry FDA boxed warnings for serious infections, malignancy, and cardiovascular events, which means some BCBSAZ medical policies actually prefer Dupixent as a first-line biologic before JAK inhibitors [18]. Tralokinumab (Adbry), an IL-13 inhibitor, is another biologic option but is typically placed on a non-preferred specialty tier.

For asthma, competing biologics include omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), and tezepelumab (Tezspire). BCBSAZ medical policy generally requires documentation of the specific asthma phenotype to guide biologic selection. The American Thoracic Society and European Respiratory Society guidelines recommend choosing among these agents based on biomarker profiles: anti-IL-5/IL-5R agents for high eosinophils, anti-IgE for allergic phenotype, and dupilumab for patients with elevated eosinophils and/or FeNO, particularly those with comorbid atopic dermatitis or CRSwNP [19].

For CRSwNP, omalizumab and mepolizumab are also FDA-approved alternatives. The Endotype-Driven Treatment (EDRN) approach, recommended by the 2021 European Position Paper on Rhinosinusitis (EPOS), suggests that dupilumab may be preferred in patients with concurrent asthma given its dual-indication benefit [20]. BCBSAZ does not mandate trying another biologic before Dupixent for CRSwNP, but step therapy through maximal medical management (intranasal steroids, saline irrigations, and potentially a course of oral steroids) is still required.